Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

NRX-101 Expanded Access

NCT: NCT05779267 · AVAILABLE

NCT IDNCT05779267
StatusAVAILABLE
SponsorNeuroRx, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this Expanded Access Treatment Protocol is to make NRX-101 available to patients who have treatment-resistant depression and who are unable to participate in, or do not have access to, the ongoing NRX-101 clinical trial. The objective of the program is to provide treatment access while monitoring safety in the context of NRX-101 administration paired with theta burst transcranial magnetic stimulation..

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑